NEUROMARK® Now with Expanded Access on UnitedHealthcare’s Medicare Advantage Policy for Posterior Nasal Nerve Ablation
Effective immediately, CPT 31242 is no longer considered experimental, removing a key barrier for ENT physicians treating chronic rhinitis.
GALWAY, Ireland, Oct. 22, 2025 /PRNewswire/ — Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that UnitedHealthcare’s Medicare Advantage policy has removed CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective immediately giving over 10 million patients access to NEUROMARK.
This policy update follows the recent Cigna coverage announcement (effective September 15) and represents another important step in improving patient access to innovative treatment options for chronic rhinitis and highlights growing payer recognition of the procedure’s therapeutic value. While the update does not establish clinical indications for coverage, it eliminates a significant obstacle that previously limited physicians from offering UnitedHealthcare’s Medicare Advantage patients posterior nasal nerve ablation.
